Header Logo

Connection

CHARLOTTE C SUN to Retrospective Studies

Back to Details
This is a "connection" page, showing publications CHARLOTTE C SUN has written about Retrospective Studies.
CHARLOTTE C SUN
Connection Strength
0.366
Retrospective Studies
  1. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol Oncol. 2022 11; 167(2):139-145.
    View in: PubMed
    Score: 0.042
  2. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic. Gynecol Oncol. 2019 02; 152(2):328-333.
    View in: PubMed
    Score: 0.032
  3. Lifestyle modification in cervical cancer survivors: an ongoing need. Int J Gynecol Cancer. 2014 Mar; 24(3):570-5.
    View in: PubMed
    Score: 0.023
  4. Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021. Gynecol Oncol. 2024 Nov; 190:255-261.
    View in: PubMed
    Score: 0.012
  5. Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States. Int J Gynecol Cancer. 2022 09 06; 32(9):1153-1163.
    View in: PubMed
    Score: 0.010
  6. Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States. Int J Gynecol Cancer. 2022 07 04; 32(7):899-905.
    View in: PubMed
    Score: 0.010
  7. Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States. Cancer. 2021 Nov 15; 127(22):4151-4160.
    View in: PubMed
    Score: 0.010
  8. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol. 2021 07; 225(1):68.e1-68.e11.
    View in: PubMed
    Score: 0.009
  9. National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer. 2020 08; 30(8):1195-1202.
    View in: PubMed
    Score: 0.009
  10. Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer. 2020 02; 30(2):187-192.
    View in: PubMed
    Score: 0.009
  11. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. Am J Obstet Gynecol. 2019 11; 221(5):474.e1-474.e11.
    View in: PubMed
    Score: 0.008
  12. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019 08; 221(2):136.e1-136.e9.
    View in: PubMed
    Score: 0.008
  13. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol. 2019 03; 152(3):439-444.
    View in: PubMed
    Score: 0.008
  14. Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer. 2018 02; 28(2):285-292.
    View in: PubMed
    Score: 0.008
  15. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
    View in: PubMed
    Score: 0.007
  16. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol. 2018 Feb; 117(2):236-244.
    View in: PubMed
    Score: 0.007
  17. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol. 2017 08; 146(2):399-404.
    View in: PubMed
    Score: 0.007
  18. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. Gynecol Oncol. 2017 04; 145(1):37-40.
    View in: PubMed
    Score: 0.007
  19. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol. 2017 04; 145(1):55-60.
    View in: PubMed
    Score: 0.007
  20. The DISINFECT Initiative: Decreasing the Incidence of Surgical INFECTions in Gynecologic Oncology. Ann Surg Oncol. 2017 Feb; 24(2):362-368.
    View in: PubMed
    Score: 0.007
  21. Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer. Abdom Radiol (NY). 2016 08; 41(8):1589-95.
    View in: PubMed
    Score: 0.007
  22. Dying well: How equal is end of life care among gynecologic oncology patients? Gynecol Oncol. 2016 Feb; 140(2):295-300.
    View in: PubMed
    Score: 0.007
  23. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):553-8.
    View in: PubMed
    Score: 0.006
  24. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol. 2015 Jan; 136(1):25-9.
    View in: PubMed
    Score: 0.006
  25. Laparoscopic supracervical hysterectomy with morcellation: should it stay or should it go? J Minim Invasive Gynecol. 2015 Feb; 22(2):185-92.
    View in: PubMed
    Score: 0.006
  26. Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. Gynecol Oncol. 2014 Nov; 135(2):244-8.
    View in: PubMed
    Score: 0.006
  27. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012 Jun; 125(3):661-6.
    View in: PubMed
    Score: 0.005
  28. Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecol Oncol. 2012 Apr; 125(1):241-4.
    View in: PubMed
    Score: 0.005
  29. Low-grade serous primary peritoneal carcinoma. Gynecol Oncol. 2011 Jun 01; 121(3):482-6.
    View in: PubMed
    Score: 0.005
  30. Outcomes of patients undergoing radical hysterectomy for cervical cancer of high-risk histological subtypes. Int J Gynecol Cancer. 2011 Jan; 21(1):123-7.
    View in: PubMed
    Score: 0.005
  31. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Gynecol Oncol. 2011 Feb; 120(2):229-32.
    View in: PubMed
    Score: 0.005
  32. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010 Aug; 116(2 Pt 1):269-273.
    View in: PubMed
    Score: 0.005
  33. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010 Jul; 17(7):1794-801.
    View in: PubMed
    Score: 0.004
  34. Survival after intestinal perforation: can it be predicted? Gynecol Oncol. 2009 Dec; 115(3):349-53.
    View in: PubMed
    Score: 0.004
  35. Parametrial involvement in radical hysterectomy specimens for women with early-stage cervical cancer. Obstet Gynecol. 2009 Jul; 114(1):93-99.
    View in: PubMed
    Score: 0.004
  36. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008 Mar; 108(3):510-4.
    View in: PubMed
    Score: 0.004
  37. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007 Jul; 246(1):52-60.
    View in: PubMed
    Score: 0.004
  38. Comparison of total laparoscopic and abdominal radical hysterectomy for patients with early-stage cervical cancer. Obstet Gynecol. 2007 Jul; 110(1):96-102.
    View in: PubMed
    Score: 0.004
  39. The learning curve in pancreatic surgery. Surgery. 2007 May; 141(5):694-701.
    View in: PubMed
    Score: 0.004
  40. The learning curve in pancreatic surgery. Surgery. 2007 Apr; 141(4):456-63.
    View in: PubMed
    Score: 0.004
  41. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006 Jun 01; 106(11):2452-8.
    View in: PubMed
    Score: 0.003
  42. Advanced cervical cancer treatment in Harris County: pilot evaluation of factors that prevent optimal therapy. Gynecol Oncol. 2006 Nov; 103(2):547-53.
    View in: PubMed
    Score: 0.003
  43. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006 Jan 19; 354(3):261-9.
    View in: PubMed
    Score: 0.003
  44. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004 Dec; 8(8):935-49; discussion 949-50.
    View in: PubMed
    Score: 0.003
  45. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer. 2004 Oct 01; 101(7):1514-23.
    View in: PubMed
    Score: 0.003
  46. Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J Am Coll Surg. 2004 Sep; 199(3):388-93.
    View in: PubMed
    Score: 0.003
  47. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol. 2004 Aug; 104(2):255-60.
    View in: PubMed
    Score: 0.003
  48. Vacuum-assisted closure in the treatment of gynecologic oncology wound failures. Gynecol Oncol. 2004 Feb; 92(2):586-91.
    View in: PubMed
    Score: 0.003
  49. Cavitational ultrasonic surgical aspiration for the treatment of vaginal intraepithelial neoplasia. Gynecol Oncol. 2000 Aug; 78(2):235-41.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.